Selective CDK4 Inhibitor Compounds for Reduced Toxicity and Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK inhibitors, such as CDK4/6 inhibitors, can cause adverse effects like gastrointestinal and hematologic toxicities and may lead to acquired resistance, necessitating the development of more effective and safer therapies for cancer treatment.
Innovation Solution
Development of compounds that selectively inhibit CDK4 and/or CDK6, potentially reducing side effects and overcoming resistance mechanisms, including pharmaceutical compositions and methods for their use in combination with other anticancer agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CDK4/6 inhibitors are used to treat cancer, then anti-cancer efficacy is improved, but gastrointestinal and hematologic toxicities occur
Solution Approach 1:
The patent segments the CDK inhibitor activity into selective CDK4 inhibition versus broader CDK4/6 inhibition. By designing compounds that specifically target CDK4 while sparing CDK6, the invention divides the inhibitory action to achieve efficacy against cancers driven by CDK4 while avoiding toxicities associated with CDK6 inhibition, particularly hematologic toxicities.
Solution Approach 2:
The patent applies local quality by creating inhibitors with differential selectivity for specific CDK isoforms. The compounds are designed to exhibit high selectivity for CDK4 in certain cancer contexts while maintaining lower activity against CDK6, thereby tailoring the biological effect to the specific pathological context and reducing off-target toxicities.
2Reliability
If CDK4/6 inhibitors are used to treat cancer, then cell cycle progression is blocked, but acquired resistance develops
Solution Approach 1:
The patent employs dynamics by developing a flexible inhibitor strategy that can adapt to different resistance mechanisms. The selective CDK4 inhibitors can be combined with various other agents (CDK6 inhibitors, endocrine therapies, chemotherapy) to dynamically adjust the treatment approach based on the development of resistance, thereby extending the duration of effective action.
Solution Approach 2:
The patent uses composite materials by combining selective CDK4 inhibitors with other anticancer agents in formulation compositions. These composite therapeutic regimens include combinations with CDK6 inhibitors, endocrine therapies, and chemotherapy agents, creating multi-component treatment strategies that overcome acquired resistance through synergistic effects.
3Object-affected harmful factors
If selective CDK4 inhibitors are developed, then drug-drug interactions are reduced, but compound specificity must be precisely controlled
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of CDK inhibitors to optimize selectivity parameters. By adjusting molecular features such as substituent groups, ring structures, and stereochemistry, the invention fine-tunes the binding affinity and selectivity profile of the compounds for CDK4 versus CDK6, achieving the desired specificity through precise structural control.
Data Source
AI summary
This invention relates to compounds of Formula (I)or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.